In further support of this, Brady et al. studied 93 stage IV NSCLC patients receiving CHT alone or in combination with BEV and observed that, while CHT was as effective in KRAS WT patients as in those with KRAS-mutant tumors, BEV improved OS and PFS in patients with KRAS WT, but not those with KRAS-mutant tumors [30]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.